Pharmacological blockade of neurotrophin receptors now constitutes the most direct strategy to exploit the tumour-intrinsic arm of the NGF–TrkA/BDNF–TrkB axis while simultaneously attenuating the immunoregulatory feedback loops described above (69, 70). This evidence concerns the gene NTRK2 and neoplasm.